Ceapro Inc.

CZO-X

Analysis and Opinions about CZO-X

Signal
Opinion
Expert
DON'T BUY
DON'T BUY
May 5, 2020
He was stopped out over a year ago. They are an emerging compunder, but didn't like their weak disclosure. He stopped looking at this. Watch your allocation size for stocks like this, because they can soar or plunge.
Show full opinionHide full opinion
He was stopped out over a year ago. They are an emerging compunder, but didn't like their weak disclosure. He stopped looking at this. Watch your allocation size for stocks like this, because they can soar or plunge.
DON'T BUY
DON'T BUY
January 11, 2019
They have a good extraction technology for taking oils from grains. They are associated to the Aveeno cosmetic brand. A nice business and he thought they would get into cannabis. When they didn't he sold out. He thinks management is not really public orientated -- they are best to be privately owned.
Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
January 11, 2019
They have a good extraction technology for taking oils from grains. They are associated to the Aveeno cosmetic brand. A nice business and he thought they would get into cannabis. When they didn't he sold out. He thinks management is not really public orientated -- they are best to be privately owned.
PAST TOP PICK
PAST TOP PICK
November 16, 2017

(A Past Top Pick Dec 2/16, Down 59%) He is going to conceded defeat on this one. The revenues and earnings have fallen. The company is not good at communicating.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
November 16, 2017

(A Past Top Pick Dec 2/16, Down 59%) He is going to conceded defeat on this one. The revenues and earnings have fallen. The company is not good at communicating.

PAST TOP PICK
PAST TOP PICK
September 18, 2017

(A Top Pick Aug 19/16. Down 70%.) Recently exited this. He likes what they do. They recently set up another plant, and thinks they have had some challenges with that. Results have been relatively weak of late, and he wasn’t terribly thrilled with the level of communication of management. However, it continues to be on his radar. Should their earnings pick up again, he would not hesitate to Buy it back.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
September 18, 2017

(A Top Pick Aug 19/16. Down 70%.) Recently exited this. He likes what they do. They recently set up another plant, and thinks they have had some challenges with that. Results have been relatively weak of late, and he wasn’t terribly thrilled with the level of communication of management. However, it continues to be on his radar. Should their earnings pick up again, he would not hesitate to Buy it back.

COMMENT
COMMENT
August 21, 2017

It is worth holding on to even though it is so frustrating. Their revenues and earnings have dripped not due to the core business, but because they used to get one off contracts for their products and have not have one in several quarters. They may get one tomorrow or in a year. There core business is doing okay. It is hard to say if they are worth the market cap. They have interesting trials going on. If that works out they will do well. There are no analysts covering the stock.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
August 21, 2017

It is worth holding on to even though it is so frustrating. Their revenues and earnings have dripped not due to the core business, but because they used to get one off contracts for their products and have not have one in several quarters. They may get one tomorrow or in a year. There core business is doing okay. It is hard to say if they are worth the market cap. They have interesting trials going on. If that works out they will do well. There are no analysts covering the stock.

PAST TOP PICK
PAST TOP PICK
July 10, 2017

(A Top Pick July 4/16. Down 42.48%.) A biotech company out of Alberta and doing some very, very interesting things. They opened a new plant, and he feels the transition from the old plant to the new one has been bumpy. They’ve thrown up 2 lacklustre quarters in a row, and there really hasn’t been a lot of communication from management. He owns a very small position. If you don’t own, wait on the sidelines until a nice quarter comes out or some sort of guidance from the company.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
July 10, 2017

(A Top Pick July 4/16. Down 42.48%.) A biotech company out of Alberta and doing some very, very interesting things. They opened a new plant, and he feels the transition from the old plant to the new one has been bumpy. They’ve thrown up 2 lacklustre quarters in a row, and there really hasn’t been a lot of communication from management. He owns a very small position. If you don’t own, wait on the sidelines until a nice quarter comes out or some sort of guidance from the company.

COMMENT
COMMENT
May 30, 2017

An extraction technology company which basically extracts compounds from food. They make the key ingredients in Aveeno cream. Has a really nice list of clients and good technology. Last quarter was a little weak, but investors didn’t understand that they are running 2 plants now, so costs were higher than normal. The real problem is that management doesn’t do a good job of telling their story. If they could scale it up, it would be a cash cow and a beautiful thing. They’ll be doing an investor update very soon, so watch for that.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
May 30, 2017

An extraction technology company which basically extracts compounds from food. They make the key ingredients in Aveeno cream. Has a really nice list of clients and good technology. Last quarter was a little weak, but investors didn’t understand that they are running 2 plants now, so costs were higher than normal. The real problem is that management doesn’t do a good job of telling their story. If they could scale it up, it would be a cash cow and a beautiful thing. They’ll be doing an investor update very soon, so watch for that.

COMMENT
COMMENT
May 25, 2017

A very high margin business. They do beta glucan that goes into Burt’s Bees, Aveeno etc. It is extracted from oats. This is a small component of a number of their products, but margins are very high. They were getting orders from a few companies in China, which ramped up their earnings. The last quarter wasn’t great. He still likes the company. It is going to be bumpy in terms of earnings.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
May 25, 2017

A very high margin business. They do beta glucan that goes into Burt’s Bees, Aveeno etc. It is extracted from oats. This is a small component of a number of their products, but margins are very high. They were getting orders from a few companies in China, which ramped up their earnings. The last quarter wasn’t great. He still likes the company. It is going to be bumpy in terms of earnings.

BUY WEAKNESS
BUY WEAKNESS
March 29, 2017

Was a top pick last year and has been consolidating recently. They bounce very hard off the $1.20 level. There is a lot of support at that level. They started a new plant to extract product from oats. There is a lot of demand for their product.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
March 29, 2017

Was a top pick last year and has been consolidating recently. They bounce very hard off the $1.20 level. There is a lot of support at that level. They started a new plant to extract product from oats. There is a lot of demand for their product.

COMMENT
COMMENT
February 28, 2017

They extract beta gluten from oats. Have had some very good earnings growth over the last year. Thinks the stock will continue to do well. They are going to expand their plant which should be coming on soon. He still likes this.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
February 28, 2017

They extract beta gluten from oats. Have had some very good earnings growth over the last year. Thinks the stock will continue to do well. They are going to expand their plant which should be coming on soon. He still likes this.

COMMENT
COMMENT
February 21, 2017

They extract the good stuff from oats for use in cosmetics. Also, extracts for use in food for reducing cholesterol. Recently increased their plant size by 10X. Still has a year’s worth of inventory stockpiled for covering risks with their new plant. There was some lumpiness in the most recent quarter with a Chinese customer not reordering. The question is, will he be back in the upcoming quarter. Thinks growth is pretty good with some interesting opportunities.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
February 21, 2017

They extract the good stuff from oats for use in cosmetics. Also, extracts for use in food for reducing cholesterol. Recently increased their plant size by 10X. Still has a year’s worth of inventory stockpiled for covering risks with their new plant. There was some lumpiness in the most recent quarter with a Chinese customer not reordering. The question is, will he be back in the upcoming quarter. Thinks growth is pretty good with some interesting opportunities.

BUY
BUY
February 16, 2017

He likes it. You want to wait until they announce some big contracts. If you own it hold on to it. He would buy it here. They are profitable.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
February 16, 2017

He likes it. You want to wait until they announce some big contracts. If you own it hold on to it. He would buy it here. They are profitable.

PAST TOP PICK
PAST TOP PICK
January 24, 2017

(A Top Pick July 4/16. Up 13.72%.) They take the active ingredients in oats and produce a compound that is an important ingredient in moisturizers and skin creams. Also, using this in a PGX technology so that it can be used in a powder formation as well. Opened a facility that will increase productivity tenfold. Last quarter was a titch weak, and suspects it was because large customers had ordered a lot of products in advance of opening the new facility. There are probably still growing pains. Trading range lately has been $1.20 - $2.00. Long term prospects are excellent.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
January 24, 2017

(A Top Pick July 4/16. Up 13.72%.) They take the active ingredients in oats and produce a compound that is an important ingredient in moisturizers and skin creams. Also, using this in a PGX technology so that it can be used in a powder formation as well. Opened a facility that will increase productivity tenfold. Last quarter was a titch weak, and suspects it was because large customers had ordered a lot of products in advance of opening the new facility. There are probably still growing pains. Trading range lately has been $1.20 - $2.00. Long term prospects are excellent.

BUY
BUY
December 20, 2016

He is one of the largest holders of the stock. It came off because they did an issue. They make chemicals that would go into a lot of P&G products. The stock has been moving up in the last few days on a lot of volume. There is still no analyst coverage. He is comfortable with the story and thinks the next couple of quarters will show more strength.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
December 20, 2016

He is one of the largest holders of the stock. It came off because they did an issue. They make chemicals that would go into a lot of P&G products. The stock has been moving up in the last few days on a lot of volume. There is still no analyst coverage. He is comfortable with the story and thinks the next couple of quarters will show more strength.

TOP PICK
TOP PICK
December 2, 2016

A biotech company, but they produce materials from oats. CEO is very impressive. Biotechs sometimes scares people, because they think they don’t make any money. This one actually makes money and is very profitable. They do 70% gross margins. Trading at about 12X earnings, and yet there is significant upside. The new plant can do 10X the revenue they currently do, so there is no CapX. As they fill the capacity use in that plant, it is going to be a free cash flow play. They are also testing different uses for the compound. Currently being used by Aveeno, but are also doing trial testing for combating high cholesterol. You are getting the stock for a very low multiple. Has $10 million cash in the bank.

Show full opinionHide full opinion
Ceapro Inc. (CZO-X)
December 2, 2016

A biotech company, but they produce materials from oats. CEO is very impressive. Biotechs sometimes scares people, because they think they don’t make any money. This one actually makes money and is very profitable. They do 70% gross margins. Trading at about 12X earnings, and yet there is significant upside. The new plant can do 10X the revenue they currently do, so there is no CapX. As they fill the capacity use in that plant, it is going to be a free cash flow play. They are also testing different uses for the compound. Currently being used by Aveeno, but are also doing trial testing for combating high cholesterol. You are getting the stock for a very low multiple. Has $10 million cash in the bank.

Showing 1 to 15 of 25 entries

Ceapro Inc.(CZO-X) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for Ceapro Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Ceapro Inc.(CZO-X) Frequently Asked Questions

What is Ceapro Inc. stock symbol?

Ceapro Inc. is a Canadian stock, trading under the symbol CZO-X on the TSX Venture Exchange (CZO-CV). It is usually referred to as TSXV:CZO or CZO-X

Is Ceapro Inc. a buy or a sell?

In the last year, 1 stock analyst published opinions about CZO-X. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is DON'T BUY. Read the latest stock experts' ratings for Ceapro Inc..

Is Ceapro Inc. a good investment or a top pick?

Ceapro Inc. was recommended as a Top Pick by Jason Del Vicario on 2020-05-05. Read the latest stock experts ratings for Ceapro Inc..

Why is Ceapro Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Ceapro Inc. worth watching?

1 stock analyst on Stockchase covered Ceapro Inc. In the last year. It is a trending stock that is worth watching.

What is Ceapro Inc. stock price?

On 2020-07-13, Ceapro Inc. (CZO-X) stock closed at a price of $0.5.